
NYSE:UN
This summary was created by AI, based on 1 opinions in the last 12 months.
Unilever NV has received mixed reviews from various experts, largely focusing on significant changes in consumer behavior and the company's strategic decisions. Specifically, the introduction of GLP-1 drugs has altered diets, leading to a decline in processed food consumption, which could negatively impact Unilever's sales. Additionally, the merger with McCormick has been deemed a failure, raising concerns about Unilever's current focus and direction. With these factors taken into account, it appears that there are significant challenges ahead for the company. Recent assessments suggest that investors might want to tread cautiously before making new commitments to Unilever shares.
The book for this is effectively 50% emerging markets and 50% developed economies. The key driver in the last few years has been the emerging markets. What has offset that have been weaker currencies. Although the penetration, market share and economics have continued to improve, the relatively little profit coming back has been less. He is a firm believer that emerging markets are going to continue to grow. It will be lumpy growth.
A great story and not an expensive stock. Trading at about 17X earnings. Has a 4.2% dividend yield. What they has done, that a lot of other companies have not done, is to restructure their assets. They’ve looked at their brands and their global businesses and made some very structural changes that are very important.